The Food and Drug Administration last week updated 2017 draft guidance to clarify the categories of clinical and decision support software subject to FDA oversight under the 21st Century Cures Act based on risk, and released final guidance on the types of software no longer considered medical devices under the Act’s amended definition of device. “We’re making clear that certain digital health technologies — such as mobile apps that are intended only for maintaining or encouraging a healthy lifestyle — generally fall outside the scope of the FDA’s regulation,” said Principal Deputy Commissioner Abernethy, M.D. “Such technologies tend to pose a low risk to patients, but can provide great value to consumers and the health care system.”

Related News Articles

Headline
The House is expected to begin a final vote Nov. 12 on the Senate-backed funding package, bringing a potential end to the government shutdown one step closer.…
Headline
The Senate Nov. 10 passed legislation to fund the federal government that will now head to the House for a vote as early as the evening of Nov. 12, as an end…
Headline
The Senate Nov. 9 took a critical first step toward ending the government shutdown as seven Democrats and Sen. Angus King, I-Maine, joined Republicans to…
Headline
Senate negotiations on a potential funding deal to end the record-long government shutdown are ongoing, and the chamber is likely to continue working through…
Headline
The AHA expressed support Nov. 3 for the bipartisan Home Health Stabilization Act (H.R. 5142), legislation that would establish a two-year pause on planned…
Headline
The AHA today submitted a letter to the Office of Science and Technology Policy in response to its request for information on regulatory reform for artificial…